title: Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review.
abstract: Uveal melanoma (UM) is the most common primary ocular tumour in adults. Despite good local control of the primary tumour with current methods, survival after the development of metastasis has remained poor over the last 30 years. After cutaneous melanoma, UM is the most common type of melanoma, and an ongoing debate exists regarding whether these conditions should be considered separate entities, particularly in the context of targeted therapy, where many of the initial trials for patients with metatatic cutaneous melanoma excluded metastatic UM. This paper will review the recent and ongoing investigations designed to validate systemic targeted therapy and immunotherapy in patients with metastatic UM and suggests ways in which these developments may affect management of UM by ophthalmologists in the near future.
authors.affiliation: School of Medicine, University of Queensland, Brisbane, Queensland, Australia.
authors.forename: Amanda Yl
authors.initials: AY
authors.lastname: Goh
authors.affiliation: School of Medicine, University of Queensland, Brisbane, Queensland, Australia.|Gallipoli Medical Research Institute, Brisbane, Queensland, Australia.|Ophthalmology Department, Greenslopes Private Hospital, Brisbane, Queensland, Australia.
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Layton
mesh_terms: D019468:Disease Management; D006801:Humans; D007167:Immunotherapy; D008545:Melanoma / Q000473:pathology / Q000628:therapy*; D058990:Molecular Targeted Therapy; D012878:Skin Neoplasms; D014604:Uveal Neoplasms / Q000473:pathology / Q000628:therapy*; D000096142:Cutaneous Malignant Melanoma; D000098943:Uveal Melanoma
keywords: choroidal melanoma; cutaneous melanoma; immunotherapy; targeted therapy; uveal melanoma